Compare iShares MSCI Taiwan ETF (EWT) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Taiwan ETF vs Novavax Inc — how do they compare? iShares MSCI Taiwan ETF trades at $106.41, while Novavax Inc trades at $7.98 (market cap $1.31B). The key difference: iShares MSCI Taiwan ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| EWT | NVAX | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $111.53 | $11.19 |
52-Week Low | $58.05 | $6.22 |
Market Cap | — | $1.31B |
Enterprise Value | — | $889.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWT (iShares MSCI Taiwan ETF) trades at $106.19, up 3.92% with strong bullish momentum from moving averages. The ETF benefits from Taiwan's AI-driven semiconductor exposure, particularly through TSMC's 22.5% weighting. Recent news highlights continued capital flows into Taiwan's tech sector despite regional volatility, with MediaTek and ASE Technology announcing significant AI-related investments.
Outlook remains positive given Taiwan's leadership in semiconductor manufacturing and AI supply chain dominance. Key risks include geopolitical tensions with China and potential rotation away from AI-heavy markets. Institutional sentiment appears constructive with selective foreign inflows supporting the ETF's premium valuation.
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Taiwan ETF
EWT tracks the MSCI Taiwan 25/50 Index, providing targeted exposure to large and mid-cap companies in Taiwan. It is heavily concentrated in the information technology sector, serving as a liquid instrument for investors seeking a single-country view of Taiwan's export-oriented and tech-driven economy.
Read more on EWT →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
